ArticleAME case reports2025
Tonsillar langerhans cell sarcoma with gastrointestinal metastasis: a rare case report.
Article in AME case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Langerhans cell sarcoma (LCS) is a rare, aggressive neoplasm of Langerhans cells with potential for multi-organ involvement. LCS appearing in the tonsils and spreading to the gastrointestinal (GI) tract is extremely rare. This report describes a case of tonsillar LCS with GI metastasis in an elderly female. Case Description: An 83-year-old female with a history of over 50 years of heavy smoking presented in February 2024 with progressive left tonsillar swelling, dysphagia, significant weight loss, and pain impacting her ability to eat. Physical examination revealed a left tonsillar mass and cervical lymphadenopathy, with an Eastern Cooperative Oncology Group performance status of 2-3. Initial neck computed tomography (CT) imaging demonstrated a 3 cm × 3.5 cm × 6.4 cm left oropharyngeal mass with extensive local invasion and necrotic cervical lymphadenopathy. Positron emission tomography-CT (PET-CT) confirmed hypermetabolic activity in the left nasopharyngeal region and further invasion. Histological examination of an incisional biopsy, from the tonsillar mass, confirmed LCS, with positive immunohistochemical markers (S100, CD1a, BCL6, Langerin) and a high Ki-67 index (90%). The patient underwent radiation therapy and pembrolizumab for metastatic control. Despite treatment, a PET-CT revealed progression with abdominal lymph node involvement, pleural effusion, and gastric wall thickening. In July 2024, she experienced acute upper GI bleeding managed with blood transfusions and supportive care, with endoscopic biopsy confirming metastatic spread. By August 2024, the patient was readmitted with an acute abdomen due to gastric perforation, leading to a transition to palliative care due to LCS progression and GI complications. The patient died six months after initial diagnosis. Conclusions: Further studies are needed to explain the pathogenesis of LCS, investigate targeted therapeutic approaches, and develop standardized management protocols for localized and metastatic LCS presentations to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.